Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Overview
US immuno-oncology firm's fiscal 2025 net loss widened yr/yr
Grant income for fiscal 2025 declined sharply from prior year
R&D expenses fell in fiscal 2025, G&A costs were almost flat
Outlook
Marker expects APOLLO study data update in Q2 2026
Company plans to initiate pancreatic cancer clinical program in Q2 2026
Company expects cash to fund operations through Q4 2026, assuming no additional grant funds are received
Result Drivers
GRANT INCOME DROP - Company said grant income declined to $3.5 mln in 2025 from $6.6 mln in 2024
LOWER R&D SPENDING - Research and development expenses fell to $11.8 mln in 2025 from $13.5 mln in 2024
Company press release: ID:nGNXcgKtHb
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income |
| -$12.2 mln |
|
FY Basic EPS |
| -$0.79 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Marker Therapeutics Inc is $10.00, about 646.3% above its March 18 closing price of $1.34
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
